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Abstract
Background and methodology High levels of 
unplanned pregnancy among young people are 
a huge public health problem in South Africa. 
However, use of emergency contraception (EC) 
remains low. Studies suggest that providers 
constitute an important link to increasing access 
to EC use. The aim of the study was to provide 
greater insights into the attitudes of providers 
towards EC in order to better understand factors 
infl uencing uptake. The study drew upon 30 in-
depth interviews with providers at private and 
public health facilities in Durban, South Africa.
Results The results of the study highlight 
several barriers to the provision of EC in both 
public and private health facilities. The cost 
of EC products in commercial pharmacies is 
likely to be a major barrier to use for many 
women. In addition, providers in both public 
and private facilities are often reluctant to 
provide EC over the counter because they 
feel that the use of EC is likely to discourage 
regular use of contraception and increase the 
risk of unprotected sexual intercourse and, as 
a result, contribute to the spread of HIV/AIDS 
in South Africa. In addition, they reported that 
they do not have an opportunity to counsel 
women about EC because of time constraints. 
Providers in both the public and private sectors 
also demonstrated a level of uncertainty 
about the clinical effects of EC pills and on 
the regulations surrounding their provision.
Discussion and conclusions Despite relatively 
progressive legislation on EC provision and 
the widespread availability of EC products in 
South Africa, providers in pharmacies, family 
planning clinics and public health clinics need 
more training on EC provision. Interventions 
should aim to educate health providers on both 
the clinical and social aspects of EC provision.
Introduction
In South Africa, the level of fertility among 
young women remains high. By the age of 
18 years, one in five women have given 
School of Development Studies, 
University of KwaZulu-Natal, 
Durban, South Africa
Correspondence to 
Prof Pranitha Maharaj, 
Associate Professor, School of 
Development Studies, University 
of KwaZulu-Natal, Durban 4041, 
South Africa; 
Maharajp7@ukzn.ac.za
Received 3 March 2010
Accepted 5 October 2010
Missing opportunities for preventing unwanted 
pregnancy: a qualitative study of emergency 
contraception
Pranitha Maharaj, Michael Rogan
birth, and more than 30% of women 
nationally have their first child before they 
attain the age of 20 years.1 2 Many births 
to mothers aged less than 20 years are 
unplanned and/or unwanted.2 3 Emergency 
contraception (EC) is known to be highly 
effective at preventing, or reducing the risk 
of, an unwanted pregnancy after unpro-
tected sexual intercourse (UPSI). This 
includes all cases of incorrect use, method 
failure (such as condom slippage, leakage 
or breakage, missing hormonal pills or an 
intrauterine device expulsion) or failure to 
use contraceptives, including in cases of 
sexual assault.4 EC, also known as post-
coital contraception or the ‘morning-after’ 
pill, has been shown to be effective for up 
to 120 hours (5 days) after UPSI. However, 
the efficacy of the contraceptive appears 
to decline with time.4 5 This makes ease of 
access to EC products a critical component 
of its effectiveness.
Legislation affecting access to EC is rela-
tively progressive in South Africa. Since 
2000, EC products have been resched-
uled to allow for over-the-counter access 
without a doctor’s prescription. There are 
two dedicated EC products available on 
the commercial market and, to a limited 
extent, in some public sector health facili-
ties. In 1999, the first dedicated EC pill was 
introduced to the South African market in 
the form of an estrogen/progestogen prod-
uct. In 2001, a  levonorgestrel-only EC pill 
with an improved side effect profile was 
made available.6 In public sector health 
Key message points
▶  Demand for emergency contraception (EC) is increasing, 
especially at pharmacies. However, cost remains a major 
barrier to access.
▶  Providers expressed several reservations about the provision 
of EC over the counter, without a prescription.
▶  There is a need for more training of providers on EC 
provision.
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facilities, EC products are available at no cost to the 
client and are usually provided in the form of ‘cut-up’ 
(i.e. repackaged) regular combined oral contraceptives 
(COCs). In commercial pharmacies, the levonorgestrel-
only product (the most expensive option), the estrogen/
progestogen product (although recently discontinued) 
and repackaged COCs are all available as EC options.
In the years since EC has been available over the 
counter without a doctor’s prescription, several stud-
ies have begun to investigate the role of health provid-
ers in facilitating access to EC.6–8 A recent review of EC 
studies in South Africa found that of the studies that 
have focused on the knowledge, attitudes and prac-
tices of providers, only two have included commercial 
pharmacists.9 One of these studies was conducted to 
examine pharmacists’ knowledge and perceptions of 
EC pills in two urban areas in South Africa 2 years 
after the method became available over the counter 
without a prescription.7 The other study was published 
shortly after EC products were deregulated and prior 
to the widespread availability of the most recent EC 
product (the levonorgestrel-only pill).8
Despite the relative ease of access to EC products in 
South Africa, most studies suggest that use is low.3 10 11 
Increasing evidence suggests that it is not simply lack 
of knowledge that results in underutilisation of EC but 
also the attitudes of health providers and their reluc-
tance to provide it.6 7 A study of adolescent mothers in 
South Africa found that the attitudes of providers play 
a critical role in facilitating access to EC.12 Provider 
knowledge and acceptance of EC constitute a crucial 
link to improving access to women who need it.12 13 
Some argue that the promotion of EC by health pro-
viders is likely to lead to greater client awareness of 
the method and also increased availability.13 In addi-
tion, health professionals have the opportunity of 
counselling EC clients on other aspects of reproduc-
tive health such as sexually transmitted infections and 
HIV/AIDS.14 However, a study of two urban health 
facilities in South Africa observed that the quality of 
contraceptive counselling was variable and that there 
appeared to be little discussion of EC.15
Given the large number of unwanted pregnancies 
that occur every year in South Africa, as in many other 
parts of the world, as a result of failure to use con-
traceptive methods, sexual assault and incorrect use 
of barrier methods, EC has a crucial role to play in 
giving women an option to avoid the negative conse-
quences of unwanted pregnancy, including the need 
for an abortion.4 The available evidence suggests that 
health providers may impede access to EC products. 
However, qualitative work that considers the perspec-
tives of a wide range of providers is still needed, espe-
cially since there has been little work directed towards 
them since the deregulation of EC products. The aim 
of the study, therefore, was to investigate health pro-
vider knowledge and attitudes towards EC as a possi-
ble factor influencing uptake in South Africa.
Methods
The study drew upon qualitative data derived from 
in-depth interviews with health providers. In total, 30 
in-depth interviews were conducted with providers at 
private clinics, commercial pharmacies, non-govern-
mental family planning clinics and public health clinics 
in the city of Durban, KwaZulu-Natal, a large metro-
politan area on the east coast of South Africa.
The sampling frame was restricted to the central 
district of Durban, as past studies have suggested that 
EC awareness and use is considerably higher in urban 
areas compared with rural areas in South Africa.6 16 As 
described elsewhere,17 this site was chosen because it 
serves as a major commercial centre in KwaZulu-Natal, 
South Africa and has the greatest range of EC products 
available. Past studies investigating EC in South Africa 
have reported difficulties in identifying providers and 
users of EC.10 The study area was therefore selected 
to ensure a high response rate among providers of EC 
since use is likely to be considerably higher in the sam-
ple area than in other parts of South Africa. As a result, 
the sample may not be representative of all health pro-
viders in Durban or to the rest of KwaZulu-Natal or 
South Africa in general.
In order to compile the sampling frame, a list of 
all pharmacies and dispensaries registered with the 
Pharmacy Council of South Africa was obtained 
and contact was made with the local and provincial 
health departments. The final list comprised a total 
of 53 pharmacies, dispensaries and clinics contained 
within the sample area. Of these facilities, only eight 
were public health facilities; the remainder were com-
mercial pharmacies or private health clinics. Some of 
these were excluded from the study either because 
they were no longer in business (n = 8) or because 
they were wholesale suppliers (n = 5) and did not pro-
vide EC pills directly to the public. In addition, four 
commercial pharmacies were excluded because they 
did not sell EC products and therefore did not wish to 
participate in the study. The refusal rate among phar-
macists that provide EC was relatively low; only six 
refusals were received and these were all due to time 
constraints. In the end, interviews were conducted 
with a total of 30 health providers. These comprised 
20 retail pharmacists, two health workers from non-
governmental organisation-operated family planning 
clinics, six nurses from public sector comprehensive 
clinics, and two nurses from public sector family plan-
ning clinics.
Prior to the interviews, permission was obtained 
from the relevant authorities. It was easier to gain 
access to the private facilities because permission was 
usually obtained from the owners or managers of the 
facility. Access to the public facilities required obtain-
ing permission not only from the local and provincial 
ministry of health but also the senior management at 
the facility. Informed consent was obtained from all the 
participating health providers prior to the interview.
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The interviews collected detailed information from 
providers including their background characteristics, 
knowledge of and attitudes to EC, and some of the fac-
tors facilitating and/or inhibiting use of EC among cli-
ents. All respondents were assured that their responses 
would be kept strictly confidential and the study would 
maintain their anonymity. An attempt was also made 
to ensure maximum privacy during the interview. Each 
interview lasted approximately 30–45 minutes. All the 
interviews were recorded with the permission of the 
respondent. Notes were also taken during the inter-
view. The recorded interviews were transcribed and 
analysed using thematic analysis, which involves cat-
egorising the data according to salient themes. Themes 
are defined as the recurrent ideas or topics that are 
detected in the material being analysed and usually 
come up on more than one occasion in a particular 
set of data.18 The transcripts are used to illustrate 




Among the participating health providers there was a 
slightly higher representation of females than males. 
The average respondent was 40 years old and had 
6 years of work experience in the health facility where 
the interview took place. Respondents in the commer-
cial pharmacies were qualified pharmacists and health 
providers in all other facilities were registered nurses. 
All of the providers reported that they had heard of 
EC and most (87%) had received some training on it. 
In most cases (92%) the providers received informa-
tion on EC as part of their training on family planning 
methods. EC is still a relatively recent component of 
family planning, and as a result it may not have been a 
part of the training of all providers. Some of the pro-
viders had received their training more than 10 years 
ago. However, a few providers reported that they had 
received training about the product at their work-
place, usually from the manufacturers of one of the 
EC products.
Availability of EC
All of the providers interviewed had heard of EC or 
the morning-after-pill and they were aware that it is 
effective in reducing the risk of pregnancy after UPSI. 
Providers seemed to have relatively good knowledge 
about when to recommend EC. Most stated that 
although an EC regimen may be started up to 72 hours 
after UPSI, it should preferably be taken within the 
first 24 hours following UPSI. Only a few providers 
knew that EC may be used up to 5 days after UPSI. 
Many of the interviewees also stressed that EC pills 
should not be used as regular contraceptives.
“We only give them in circumstances of unprotected inter-
course if it happened within the last 72 hours. We provide 
ECs in the case of rape or a burst condom. We do not 
provide it if a person is not using a method of contracep-
tion and they say ‘Can you give it to me I am going to have 
unprotected sex tomorrow?’ No, we do not give it in that 
case.” [Commercial pharmacist]
The choice of EC products appears to be fairly lim-
ited, particularly in public sector facilities. In public 
health clinics, EC is provided almost exclusively in the 
form of ‘cut-up’ regular COCs. Very few public sec-
tor health providers were even aware that a dedicated 
EC product was available in South Africa. In private 
pharmacies, both COCs and the dedicated levonorg-
estrel-only product are available to clients. In private 
facilities, providers argue that despite the improved 
side effect profile of the dedicated product, there is 
a higher demand for ‘cut up’ regular COCs than for 
dedicated EC products. Cost is a major factor influenc-
ing choice of EC products.
“The price of the product is the main consideration at the 
moment. Almost 99% of the time people have already 
used the ‘cut-ups’ or their friends have used it and they 
come and ask for it by name. The costs are much lower for 
‘cut-ups’.” [Commercial pharmacist]
The costs of dedicated EC products are considerably 
higher but they require a single dose, and according 
to the providers are associated with fewer side effects. 
In addition, providers in private facilities suggest that 
compliance is higher with dedicated products. The use 
of non-dedicated products requires the administration 
of two doses within 120 hours of UPSI, with a 12-hour 
interval between doses. Pharmacists observed that this 
reduced the effectiveness because some clients do not 
adhere to the instructions.
“People have problems with regular combined oral contra-
ceptives because there are multiple doses. Clients have to 
take the second dose after 12 hours and not all of them are 
compliant. We have had cases where people had lost the 
second dose or the box.” [Commercial pharmacist]
Providers in public health facilities report that demand 
for EC products is very low and that this is likely related 
to the inability to offer walk-in EC services. In most 
public facilities there is a long waiting period, which 
may discourage use of EC products. Clients often have 
to wait in long queues before they receive EC.
“It is very rare to find a client requesting EC. We usually 
give it to the client who reports having unprotected sex: 
either the condom burst or she was not using any other 
contraceptive method.” [Public health provider]
Conversely, providers in private facilities report that 
requests for EC are common and on the rise, especially 
among young women aged between 18 and 30 years. 
They noted that women are more likely to request EC 
but there is also a growing demand among male part-
ners. [NB. This finding is supported by results from 
South Africa’s most recent Demographic and Health 
Survey, which suggests that men in the age group 15–59 
years report higher levels of ‘ever use’ of emergency 
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is that the demand is great among young people aged 
18–25 who are relatively educated about HIV/AIDS. So 
it concerns me that despite the education, there is not the 
slightest fear about the possibility of contracting HIV.” 
[Commercial pharmacist]
One provider at a commercial pharmacy remarked 
that the facility only offered dedicated EC products 
because “we try to discourage people from using it. We 
use the high costs [of the dedicated product] as a means 
of preventing people from using it”. Conversely, sev-
eral providers in the public sector felt that EC use was 
low because the option of termination of pregnancy is 
more popular, particularly among young women. As 
one public health provider argued:
“I think, as I have said, they are well aware of EC now, 
but I think that there are other options that they can use, 
like termination. It is very rare that they think about it 
now because they know that there is another option if they 
do happen to fall pregnant. There is always termination. 
So they do not stress about it. The teenagers especially 
do not stress about it. This is why I think EC use is very 
rare because abortion is one big option.” [Public health 
provider]
A few providers expressed uncertainty about EC and 
were not entirely comfortable with providing EC but 
they felt that they were not able to change the situa-
tion. This attitude was captured by one provider in a 
public facility who stated that: “At the end of the day 
we are here to offer a service. The client has come for 
a service and it is their right to receive it”. In South 
Africa, health providers are required by legislation to 
provide EC without restrictions. However, most pro-
viders in the private facilities reported that they do 
not usually counsel clients about the role of EC in pre-
venting unwanted pregnancy after UPSI because of the 
high client load. When clients request EC the providers 
give it to them but often do not voluntarily offer them 
additional information about it. However, providers 
reported that it was not possible to restrict frequent 
use of EC because of their high client load.
“I wish I could restrict the number of times that EC is 
prescribed to an individual, but in terms of the current 
circumstances it is not possible. The pharmacy is too busy 
and most often we do not always remember the people 
who request EC. And we often do not have time to take 
down a profile.” [Commercial pharmacist]
A few providers also expressed concerns about the side 
effects of EC. They felt that inappropriate or frequent 
use of EC may lead to health problems. One pharmacist 
incorrectly stated that multiple use of EC increases the 
risk of cancer, and as a result was reluctant to provide 
clients with repeat dosages. Others were concerned 
about the impact of EC on hormone levels.
“If you are using EC on a continuous basis I think it poses 
a health risk. I can provide counselling to a woman in one 
week but in the next week she can go to another pharmacy 
where the pharmacist will not know her and counsels her 
contraception (1.4% of men aged 15–59 years reported 
ever using EC compared with just 0.5% of women aged 
15–49 years).]3 Older women are more likely to be using 
a long-term contraceptive method, and according to the 
providers they sometimes request EC if they experience 
method failure but, in general, are not typical EC cli-
ents. As one public health provider explained:
“When you are in your 30s you are usually more mature. 
You are usually more stable in your job and you know that 
you cannot afford to fall pregnant because of the financial 
implications. So you are either on a contraceptive already 
or you have taken the necessary precautions. I think I may 
see only one or two a year in that age group.” [Public 
health provider]
Perceptions of EC
In general, providers, particularly in public sector 
facilities, were in favour of improving the availability 
of EC services and were aware of the potential benefits 
of EC in preventing unplanned and often unwanted 
pregnancies. However, most providers expressed mis-
givings about the use of EC. Moreover, the conditions 
under which providers were willing to supply EC were 
often narrowly defined, and none of the providers in 
the private or public health facilities reported supply-
ing an advance dosage for clients.
“I do not have a problem with EC for the simple reason 
that I would rather cope with one mistake than two. I 
would rather she came here not having used a method 
and wanting EC than the client having an unwanted 
pregnancy; because that is likely to lead to problems. 
Otherwise we are going to have mega social problems 
which we are already encountering now. So to avert that 
possibility I have no hesitation in providing EC.… [But] 
I do not believe clients should be given an advance dose 
of EC. I think they should come to the clinic when they 
need it because you get an opportunity to counsel them.” 
[Public health provider]
Almost one-third of providers expressed concern that 
the increased availability of EC might impact negatively 
on clients’ behaviour. They were particularly con-
cerned that increased accessibility of EC will lead to an 
increase in risky sexual behaviour or a reduction in the 
use of other (particularly barrier) methods of contra-
ception. This was especially worrying to providers in 
view of the high rate of HIV/AIDS infections in South 
Africa. Some providers, for example, commented:
“Obviously EC encourages risky behavior. When they come 
in to request EC it is clear that they are having unpro-
tected sex, and in South Africa unprotected sex is a risk 
because of the high levels of HIV infection.” [Commercial 
pharmacist]
“It is good that you cannot advertise EC products. If 
 everybody knew that this is available you tempt them and 
obviously sales will go up but there will be an increase in 
sexually transmitted diseases.” [Commercial pharmacist]
“I do not feel uncomfortable giving it but it concerns me 
that there is such a high demand only because of the high 
levels of HIV infections. What is particularly worrying 
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and clients are often not given a full range of contra-
ceptive options. In addition, EC cannot be advertised 
and, according to many providers, this is a major fac-
tor that is limiting awareness of the product in both 
urban and rural areas.
Many of the providers in the public health facili-
ties felt that they were ideally placed to promote EC. 
However, the heavy client load and the severe short-
age of trained staff serve as an obstacle to the pro-
motion of EC. Many providers stated that the long 
queues at public health facilities discourage them 
from counselling clients about the risks associated 
with UPSI.
“Ideally I should be going into details and saying that: 
‘These are the methods that we have available. This is 
what you should be on. If you have unprotected sex this is 
what should be done’. However, sometimes we do not have 
the time. In most cases, we do not have time to provide 
detailed information and education because of staff short-
ages and increased workload.” [Public health provider]
Providers at public facilities reported that clients are 
more likely to obtain EC from pharmacies than public 
clinics. It is easier to obtain EC from pharmacies because 
clients do not have to queue for a long period of time. 
However, clients have to pay for EC products that they 
obtain at pharmacies and they do not receive informa-
tion about the product. In contrast to the view that heavy 
workloads and staff shortages prevent public sector 
health providers from counselling EC clients, one public 
health provider outlined the advantage of EC provision 
in the public sector as being a source of information.
“A lot of clients will come here because they get informa-
tion from us. We counsel clients and help them make an 
informed decision whereas at the pharmacies it is a matter 
of ‘here is my money’ and ‘here is the product’. I think that 
clients appreciate the services they receive from us. They 
know that they are going to encounter side effects – they 
can cope with them because we have explained the side 
effects. They more or less know what to expect and are 
comfortable with it.” [Public health provider]
Conversely, the consultation with the provider, partic-
ularly in pharmacies, is often very short, lasting only a 
few minutes and not allowing sufficient time to counsel 
clients about the benefits of EC. As a result, some pro-
viders tend to give clients a fact sheet which contains 
all the relevant information about the product. On the 
whole, in both the private and public sectors, providers 
are faced with heavy client loads, which makes it dif-
ficult for them to give each client personal attention. 
Clients rarely have an opportunity to ask any ques-
tions about their concerns. In addition, some clients 
are embarrassed to be seen obtaining EC. Sometimes 
the lack of privacy may affect clients’ willingness to 
provide sensitive information. Other clients may listen 
in on the consultation and clients in the consultation 
may feel uncomfortable revealing the real reason for 
visiting the clinic.
as well. The next week she can go to another pharmacy 
to get her supply of EC. This can throw her whole cycle 
into complete disarray and increase the risk of cancer.” 
[Commercial pharmacist]
A few providers observed that they would prefer to 
advocate EC rather than termination of pregnancy. 
Although most providers knew that EC does not 
cause abortion, a few perceived that EC may be a 
form of abortion or may cause harm to a fetus if 
taken too late.
“I am on the fence about it. I do it, but at the back of 
my mind I am thinking ‘Is this person pregnant? I hope 
that I am not causing any adverse effects to the fetus’. 
However, I would rather issue EC than perform termina-
tion.” [Commercial pharmacist]
In some cases, providers also reported refusing to sup-
ply EC to clients, often as a result of uncertainty about 
the age at which a client can purchase EC products 
without a guardian’s consent. They reported that they 
often referred young men and women to the clinic 
for more effective methods of contraception. In two 
cases, providers were unaware that EC could be pro-
vided without a doctor’s prescription and as a result 
regularly refused provision. Perhaps the largest degree 
of uncertainty among providers, however, was around 
the age of clients that request EC. In fact, the majority 
of providers in both the public and private health facil-
ities expressed great concern about supplying young 
people, in particular, with EC. They often used age 
restrictions to limit EC use among this stratum of the 
population.
“I feel uncomfortable about prescribing it to a young per-
son who is under 16 years but I try to separate my per-
sonal and professional view. They need to be older than 18 
for me to accept that they can make their own decision in 
their own capacity. If they are younger I usually refer them 
to a clinic or somebody that can give consent but most of 
the time it is impossible for them to get consent, because 
of stigma. Most people do not want to go to the clinic if it 
is a small community. Apparently people are uncomfort-
able with the lack of privacy in these clinics and that all 
people are known in these communities and they do not 
want to be stigmatised.” [Commercial pharmacist]
Barriers to EC use
Despite their concerns with providing EC, health pro-
viders were able to identify a number of barriers that 
EC users are likely face in South Africa. Many of the 
pharmacists felt that young people do not receive suf-
ficient information about EC and contraception, more 
generally, and they argued that there is a need for pro-
grammes to create greater awareness of the correct use 
of EC, particularly in rural areas. Many people have 
heard of EC but they lack detailed information about 
the method, which is illustrated by the comment of 
one provider: “Most people have heard of it but they 
may not know how long after unprotected sex they 
should use it”. In rural areas, access to EC is limited 
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was reported to be a constraint to adequate counselling 
of EC clients. Almost all providers in the pharmacies 
complained of not having time to counsel EC clients 
and the great majority of pharmacies did not have a 
private counselling room in the facility.
Long waiting times for consultation at public clinics 
is another likely reason for the low uptake of EC in 
the public health sector. Long waiting times have been 
shown to discourage potential clients from seeking 
services.19 This is likely to be particularly important 
for potential EC clients as timely access is an important 
component of the treatment. Moreover, some provid-
ers may be constrained in the advice they can offer by 
their lack of adequate training. As a result, they are 
unable to offer clients a comprehensive range of serv-
ices. Moreover, the large client loads make it difficult 
for providers to offer additional information to clients. 
Under the pressure of a long queue, it is hardly surpris-
ing that most providers deal as efficiently and quickly 
as possible with patients’ explicit needs before moving 
to the next patient.
Both pharmacists and public health workers 
expressed a number of concerns with supplying EC, 
with the most common perhaps being that repeat use 
of EC might be harmful to women and could discour-
age regular contraception use. This particular theme 
has also been noted in the international literature on 
EC despite the fact that no studies have found a direct 
link between EC use and regular UPSI.20 21 Indeed, 
one European study even found that EC use was the 
catalyst to adopting more regular forms of contracep-
tion.22 Despite the evidence demonstrating that EC 
is clinically safe, is not linked with cancer23 and has 
no adverse effects, the ‘gate-keeping’ of EC products 
is a relatively common practice among the providers 
participating in the study. Some of the main reasons 
given for limiting or restricting access to EC products 
included: fears of repeat use by clients, the safety of 
EC products, uncertainty regarding the regulations 
surrounding EC, a feeling that EC use encourages pro-
miscuity, and a reluctance to provide EC to younger 
women. The fact that age was a concern for a number 
of pharmacists and public health providers, despite 
the fact that the number of unplanned and sometimes 
unwanted pregnancies is high among young women, is 
particularly worrying.
One of the key findings of the study is that provid-
ers in pharmacies, family planning clinics and public 
health clinics need more training on EC provision. 
In addition to the clinical information that providers 
themselves indicated that they would like to have, the 
growing number of studies that have shown that EC 
use does not discourage regular contraception use and 
does not lead to risky sexual behaviour should also be 
communicated to providers.20 22 24 The present study 
found that many providers felt that EC promoted 
promiscuity and UPSI. As such, many of the narra-
tives presented in this paper demonstrate the palpable 
“Consultations last approximately one minute. Most [cli-
ents] do not have the time. They do not want to listen to 
a whole long story. They want the stuff and they want to 
leave. And some of them are embarrassed.” [Commercial 
pharmacist]
Some of the providers also reported that they would 
like to receive more information on EC in order to 
improve the client–provider relationship. However, 
providers may be constrained in the advice that they 
can offer by their lack of training. Some providers had 
completed their training prior to the availability of EC 
products in South Africa. As a result they felt that there 
was an urgent need for refresher training to update 
providers on new contraceptive technologies. Some 
providers also felt that they would like to receive more 
information about the side effects of EC.
“As a pharmacist there is not much emphasis put on EC, 
and these new contraceptive methods. I qualified before 
EC was introduced. The mechanisms of it are, I would not 
say sketchy, but I would like to receive more information 
on it.” [Commercial pharmacist]
Discussion
As part of a larger study investigating the context of 
EC provision and use in South Africa, this paper offers 
several contributions to the existing literature on EC in 
South Africa. First, the study is unique in that, to the 
best of the authors’ knowledge, it is the only EC study 
in South Africa to conduct research with commercial 
pharmacists, public sector health providers, and spe-
cialised family planning providers. Second, while the 
results cannot claim to be generalisable, the strength of 
the paper lies in the qualitative design that offers some 
valuable insights into factors influencing EC use by 
drawing upon in-depth interviews with a wide range 
of EC providers. Third, the study gathers recent data 
from health providers in a site in which EC provision 
is likely to be relatively common compared with other 
parts of the country. Finally, the study offers insight 
into the provision of EC nearly 10 years after both the 
introduction of a dedicated EC pill in South Africa and 
the passing of legislation making EC products available 
without a doctor’s prescription.
There are some indications that there is an increas-
ing demand for EC, especially at private facilities. 
Pharmacies remain the key access point for EC prod-
ucts and, tellingly, product price is a main consideration 
for many EC clients. As in other local studies,6 10 11 EC 
use in public sector clinics and facilities was found to 
be very low, despite the fact that the majority of South 
African women rely on the public health sector for their 
contraceptive supplies. The greater accessibility of EC 
at pharmacies notwithstanding, the cost of EC prod-
ucts in pharmacies is likely to be prohibitive for many 
women, and the fact that some pharmacists reported 
using the higher cost of the dedicated product as an 
access barrier is a major concern. In both commercial 
pharmacies and public health clinics, consultation time 
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uncertainty that many providers have in providing EC 
to their clients, despite its recent deregulation. Some 
of the reservations about EC are also related to con-
cerns about the risk of UPSI in the context of a high 
HIV prevalence in KwaZulu-Natal.
It is important to note some of the limitations of this 
study. The findings of the study may have limited gen-
eralisability to other populations because of the small 
sample size. Moreover, the study site was specifically 
chosen in order to facilitate access to health providers 
where EC is most likely to be supplied. It is not unlikely 
that health providers who did not participate in the 
study may be less likely to provide EC. Interpretation 
of the findings is also limited by provider’s self-reports. 
It is also possible that social desirability may have 
altered the reporting of attitudes towards EC to some 
extent. As in other studies,10 providers in public health 
facilities reported supplying EC only in very rare cases 
and only perhaps once or twice a year. As a result, 
recall bias may be a particular problem among these 
health providers. In terms of the limitations associated 
with interviewing commercial pharmacists, difficulties 
such as a lack of privacy, frequent interruptions and 
some degree of suspicion towards the research proc-
ess all may have compromised the findings to a cer-
tain degree. Some of these challenges involved with 
researching EC access in pharmacies have also been 
documented in the international literature.25
Overall, however, the results of the present study 
suggest that much more emphasis should be placed 
on obtaining provider support for EC. This is likely to 
be an important lesson in other contexts where EC is 
available over the counter without a prescription. The 
findings presented here suggest that the availability of 
dedicated EC products and access to EC pills without 
a doctor’s prescription are not enough. Health provid-
ers need to be able not only to provide EC, but they 
must be comfortable enough to promote the use of EC, 
particularly among those at high risk of an unwanted 
pregnancy. The adequate training of health care provid-
ers, both within and outside the public health sector, 
is therefore an essential step in improving EC uptake. 
The fact that the majority of providers in this study 
expressed a strong interest in obtaining more informa-
tion about EC is encouraging in this regard.
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